Actavis, AstraZeneca deal

AstraZeneca will acquire U.S. and Canadian rights to Actavis’ branded respiratory portfolio in a deal slated to close this quarter. Actavis will receive an upfront payment of $600 million and will be eligible for low single-digit royalties above an undisclosed revenue threshold. Actavis will also receive $100 million for contractual consents and approvals, including amendments to ongoing collaboration agreements. ...